Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels

被引:18
|
作者
She, Wong Hoi [1 ]
Chan, Albert Chi Yan [1 ,2 ]
Cheung, Tan To [1 ,2 ]
Lo, Chung Mau [1 ,2 ]
Chok, Kenneth Siu Ho [1 ,2 ]
机构
[1] Univ Hong Kong, Dept Surg, 102 Pok Fu Lam Rd, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Hong Kong, Peoples R China
关键词
Alpha-fetoprotein; Liver transplantation; Recurrence; Survival;
D O I
10.4254/wjh.v10.i2.308
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To investigate the impact of alpha-fetoprotein (AFP) on long-term recurrence rate and overall survival and we also aimed to define the level of AFP leading to a higher risk of disease recurrence and affecting patient survival. METHODS Data of adult patients who received liver transplant (LT) for hepatocellular carcinoma (HCC) at our hospital from January 2000 to December 2013 were reviewed. Reviewed data included demographic characteristics, preoperative AFP level, operative details, follow-up details, and survival outcomes. Patients were mostly listed for LT based on Milan or UCSF criteria. For the purpose of this study, normal AFP level was defined as AFP value < 10 ng/mL, high AFP level was defined as AFP value >= 10 to < 400 ng/mL, and very high AFP level was defined as AFP >= 400 ng/mL. The patients were divided into these 3 groups accordingly. Survival rates were plotted as Kaplan-Meier curves and compared by log-rank analysis. Continuous variables were expressed as median (interquartile range). Categorical variables were compared by Spearman's test. Discriminative analysis was used to define the lowest value of AFP that could affect the overall survival in study population. Statistical significance was defined by a P value of < 0.05. RESULTS Totally 250 adult patients underwent LT for HCC in the study period. Eight-four of them received deceased-donor LT and 166 had living-donor LT. The patients were divided into 3 groups: Group A, AFP < 10 ng/mL (n = 83); Group B, AFP >= 10 to < 400 ng/mL (n = 131); Group C, AFP >= 400 ng/mL (n = 36). The commonest etiology was hepatitis-B-related cirrhosis. The Model for End-stage Liver Disease scores in these groups were similar (median, 13 vs 13 vs 12; P = 0.745). The time to operation in Group A was longer (median, 94 vs 31 vs 35 d; P = 0.001). The groups were similar in hospital mortality (P = 0.626) and postoperative complication (P = 0.702). Pathology of explants showed that the 3 groups had similar numbers of tumor nodules, but the tumors in Group C were larger (A: 2.5 cm, B: 3.0 cm, C: 4.0 cm; P = 0.003). Group C had a bigger proportion of patients who were beyond Milan criteria (P = 0.010). Poor differentiation and vascular permeation were also more common in this group (P = 0.017 and P = 0.003 respectively). It also had poorer 5-year survival (A: 85.5%, B: 82.4%, C: 66%; P = 0.029). The 5-year disease-free survival was 84.3% in Group A, 80.1% in Group B, and 61.1% in Group C. Receiver operating characteristic area under the curve for AFP in predicting tumor recurrence was 0.685. The selected cut-off value was 54 ng/mL for AFP (C-index 0.685; 95% CI: 0.592-0.779; sensitivity 0.595; specificity 0.687). On discriminative analysis, AFP value of 105 ng/mL was shown to affect the overall survival of the patients. CONCLUSION HCC patients with a high preoperative AFP level had inferior survival after LT. AFP level of 54 ng/mL was associated with disease recurrence, and AFP level of 105 ng/mL was found to be the cut-off value for overall survival difference.
引用
收藏
页码:308 / 318
页数:11
相关论文
共 50 条
  • [41] Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma
    Hakeem, A. R.
    Young, R. S.
    Marangoni, G.
    Lodge, J. P. A.
    Prasad, K. R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (09) : 987 - 999
  • [42] Serial alpha-fetoprotein evaluation and survival in hepatocellular carcinoma patients treated with sorafenib
    Personeni, N.
    Bozzarelli, S.
    Giordano, L.
    Rimassa, L.
    Pressiani, T.
    Tronconi, M. C.
    Sclafani, F.
    Carnaghi, C.
    Santoro, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 394 - 395
  • [43] The serum alpha-fetoprotein as predictor of tumor recurrence after liver transplantation for hepatocellular carcinoma
    Schraiber, Luciana S.
    Mattos, Angelo A.
    Zanotelli, Maria L.
    Cantisani, Guido Pio G.
    Brandao, Ajacio B.
    Marroni, Claudio A.
    Kiss, Guilhermo
    Ernani, Lucas
    Lionco, Livia C.
    HEPATOLOGY, 2014, 60 : 887A - 887A
  • [44] Racial differences in alpha-fetoprotein levels in cirrhotic patients with and without hepatocellular carcinoma
    Gor, Niraj
    Guzman, Grace
    Cotler, Scott
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S189 - S190
  • [45] EFFECT OF SURGICAL AND CHEMOTHERAPEUTIC TREATMENT ON ALPHA-FETOPROTEIN LEVELS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
    MCINTIRE, KR
    VOGEL, CL
    PRIMACK, A
    WALDMANN, TA
    KYALWAZI, SK
    CANCER, 1976, 37 (02) : 677 - 683
  • [46] Serum alpha-fetoprotein levels correlate with dedifferentiation in hepatocellular carcinoma
    Looi, LM
    Cheah, PL
    Goh, KL
    Rosmawati, M
    Vijeyasingam, R
    22ND WORLD CONGRESS OF PATHOLOGY & LABORATORY MEDICINE, 2003, : 295 - 297
  • [47] Correlation between serum alpha-fetoprotein variant levels in patients with hepatocellular carcinoma and the presence of alpha-fetoprotein mRNA in the circulating blood
    康晓燕
    殷正丰
    钱海华
    吴宗娣
    虞紫茜
    吴孟超
    中华肝脏病杂志, 2003, (01) : 20 - 22
  • [48] High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma
    Czauderna, Carolin
    Schmidtmann, Irene
    Koch, Sandra
    Pilz, Lukas
    Heinrich, Sophia
    Otto, Gerd
    Mittler, Jens
    Lang, Hauke
    Kloeckner, Roman
    Dueber, Christoph
    Sprinzl, Martin F.
    Worns, Marcus A.
    Galle, Peter R.
    Marquardt, Jens U.
    Weinmann, Arndt
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2021, 9 (03) : 388 - 397
  • [49] Alpha-Fetoprotein Level as the Sole Predictor of Tumor Recurrence and Survival after Liver Transplantation for Patients with Hepatocellular Carcinoma beyond Milan Criteria
    Park, Yong Keun
    Kim, Bong-Wan
    Park, Je Hoon
    Xu, Weiguang
    Wang, Hee-Jung
    TRANSPLANTATION, 2015, 99 : 225 - 225
  • [50] Markedly elevated alpha-fetoprotein levels without hepatocellular carcinoma
    Cheema, AW
    Hirschtritt, T
    Van Thiel, DH
    HEPATO-GASTROENTEROLOGY, 2004, 51 (60) : 1676 - 1678